





Researchers:

DR. FATANAH MOHAMAD SUHAIMI
 Dr. Mohd Zulfakar Mazlan
 Dr. Syatirah Mat Zin
 Nur Jihan Mohd Zukhi

INTELLECTUAL PROPERTY:
TRADEMARK (TM2019029377) ▶
COPYRIGHT (LY2018005625) ▶
NOTIFICATION NUMBER (CRLY00015600) ▶
PATENT SEARCH ▶

GlucoPro™



INTRODUCTION

GlucoPro™ is a mobile application of automated glycemic controller for monitoring and managing the glycemic level of ICU patients

PROBLEM STATEMENT

- ICU patients require highly monitoring system and careful administration because of their highly dynamic condition
- Heavy workloads and stress in the ICU may cause incorrect insulin dosage and improper timing of administration
- Improper dosage and timing error affect patient status. The risk also includes hypoglycemia episodes, which may increase mortality and morbidity

NOVELTY AND INVENTIVENESS

- GlucoPro™ is an automated glycemic control protocol for ICU
- GlucoPro™ provides automatic calculation of insulin dosage, nutrition intake and measurement interval accounting patient-specific parameter
- GlucoPro™ predicts blood glucose level using the glucose-insulin mathematical model

INTELLECTUAL PROPERTY (IP) STATUS

- Trademark: Application Number (TM2019029377)
- Copyright: Application Number (LY2018005625), Notification Number (CRLY00015600)
- Patent search has been done.

USEFULNESS AND APPLICATION

- GlucoPro™ provides a recommendation of insulin dosage, nutrition and time interval for controlling the glycemic level of a patient
- It improves the precision of glycemic control
- It reduces nursing workload and manual calculation error
- Ready to be used in clinical settings

STATUS OF INVENTION

- Technology Readiness Level (TRL) is stage 6.
- GlucoPro™ has been tested in the Universiti Sains Malaysia Hospital (HUSM) and has obtained approval to be applied at the IIUM Medical Centre

COMMERCIAL POTENTIAL

- Most of the ICU adopt a sliding scale method. Currently, there is no automated glycemic control system use for glycemic control, particularly in Malaysia
- The advantages of GlucoPro™ include easy-access of a patient record, real-time analysis of glycemic level and control, provide an alert system for clinical intervention, and reduce clinical burden.

POTENTIAL PARTNERS

- Government Hospital and Private Medical Centre

KNOWLEDGE MANAGEMENT

- This product is financially supported by the Prototype Development Research Grant Scheme (PRGS) – MOHE (203.CIPPT.674004)
- Outputs: Scientific publications, postgraduate student (PhD)

IMPACT OF THE PRODUCT

- Reduce nursing workload
- Provide better clinical management for controlling the glycemic level
- Increase economy growth

Contact Person

DR. FATANAH MOHAMAD SUHAIMI
 Advanced Medical & Dental Institute (AMDI), Bertam Campus,
 Universiti Sains Malaysia, MALAYSIA
 Tel: +604-562 2561 Fax: +604-562 2349
 E-mail: fatanah.suhaimi@usm.my